Amanote Research
Register
Sign In
252 Development of a Comprehensive New Endpoint for the Evaluation of New Treatments for Acute Decompensated Heart Failure: Results With Levosimendan in the REVIVE-1 Study
European Heart Journal
- United Kingdom
doi 10.1016/s0195-668x(03)93735-3
Full Text
Open PDF
Abstract
Available in
full text
Categories
Cardiovascular Medicine
Cardiology
Date
March 1, 2003
Authors
M PACKER
Publisher
Elsevier BV
Related search
Could Circulatory Syndecan-1 Be a Predictable Biomarker for Acute Kidney Injury in Patients With Acute Decompensated Heart Failure?
Circulation Journal
Medicine
Cardiovascular Medicine
Cardiology
Effect of Nesiritide in Patients With Acute Decompensated Heart Failure
New England Journal of Medicine
Medicine
Care of the Lower Extremities in Patients With Acute Decompensated Heart Failure
Critical Care Nurse
Medicine
Critical Care Nursing
Effects of Levosimendan Versus Dobutamine on Left Atrial Function in Decompensated Heart Failure
Canadian Journal of Cardiology
Cardiovascular Medicine
Cardiology
Intensification of Medication Therapy for Cardiorenal Syndrome in Acute Decompensated Heart Failure
Journal of Cardiac Failure
Cardiovascular Medicine
Cardiology
Cognitive Status in Patients Hospitalized With Acute Decompensated Heart Failure
American Heart Journal
Cardiovascular Medicine
Cardiology
Management of Acute Decompensated Heart Failure in the Cardiac Intensive Care Unit: The Importance of Co-Management With a Heart Failure Specialist
CJC Open
Cardiovascular Medicine
Cardiology
A Canadian Context for the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF) Trial
Canadian Journal of Cardiology
Cardiovascular Medicine
Cardiology
Comparative Pharmacoeconomic Analysis of Medication for Patients After Acute Decompensated Heart Failure
Russian Journal of Cardiology
Cardiovascular Medicine
Cardiology
